| Quarterly Financials | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 52 | 62 | 81 | 111 | 109 | 127 | 109 | 99 | 90 | 92 | 122 | 125 | 115 | 97 | 85 | 103 | 107 | 84 | 86 | 109 | 118 | 125 | 133 |
| Expenses | 41 | 54 | 56 | 84 | 81 | 88 | 81 | 77 | 73 | 79 | 103 | 112 | 93 | 76 | 73 | 83 | 93 | 78 | 79 | 99 | 100 | 101 | 106 |
| EBITDA | 11 | 8 | 25 | 27 | 28 | 39 | 29 | 22 | 17 | 13 | 19 | 14 | 22 | 21 | 12 | 20 | 14 | 6 | 7 | 10 | 19 | 23 | 27 |
| Operating Profit % | 20 % | 11 % | 31 % | 23 % | 24 % | 29 % | 23 % | 22 % | 17 % | 12 % | 15 % | 10 % | 19 % | 21 % | 13 % | 16 % | 12 % | 7 % | 8 % | 8 % | 15 % | 18 % | 19 % |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 9 | 9 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit Before Tax | 8 | 6 | 23 | 24 | 24 | 35 | 26 | 19 | 14 | 9 | 14 | 8 | 13 | 11 | 5 | 14 | 7 | -1 | -0 | 2 | 9 | 14 | 18 |
| Tax | 2 | 2 | 2 | 3 | 1 | 3 | 3 | 2 | 4 | 2 | 3 | -9 | 4 | 3 | 2 | 4 | 2 | -0 | -0 | 1 | 3 | 4 | 3 |
| Net Profit | 7 | 4 | 21 | 21 | 23 | 32 | 23 | 18 | 10 | 7 | 12 | 17 | 10 | 8 | 4 | 10 | 5 | -1 | 0 | 1 | 7 | 10 | 15 |
| EPS in ₹ | 3.34 | 1.77 | 10.39 | 10.51 | 11.52 | 15.02 | 10.29 | 7.90 | 4.42 | 3.21 | 5.24 | 7.65 | 4.29 | 3.43 | 1.48 | 4.11 | 2.23 | -0.29 | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 |
Tatva Chintan Pharma
Tatva Chintan Pharma
1,095.60
-42.00
(-3.69%)
Market Cap
2,562.83 Cr
PE Ratio
81.33
Volume
56,151.00
Day High - Low
1,125.00 - 1,064.80
52W High-Low
1,610.00 - 621.00
Key Fundamentals
Market Cap
2,562.83 Cr
EPS
2.44
PE Ratio
81.33
PB Ratio
3.53
Book Value
322.50
EBITDA
36.50
Dividend Yield
0.09 %
Industry
Chemicals Sector
Specialty Chemicals Return on Equity
0.77
Debt to Equity
0.03
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
Tatva Chintan Invests Rs 4 Crore in Green Energy
Feb 18, 2026
Feb 18, 2026Tatva Chintan Pharma Chem acquires 10.99% stake in AMPIN C&I Power Twenty Six for Rs 4 crore to source renewable energy under Group Captive Power Scheme, securing 3.2 MW solar and wind power.
Tatva Chintan Pharma Chem Limited files insider trading disclosure under SEBI regulations following inter-se transfer of 7,15,345 equity shares between promoter entities.
Ajay Mansukhlal Patel proposes to acquire 7,15,345 equity shares (3.06%) in Tatva Chintan Pharma Chem through inter-se transfer from HUF dissolution, scheduled for February 6, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,386.40 | #1 1,41,095.87 | 63.08 | 13,387.50 | 6.91 | #1 2,096 | 11.97 | 32.08 | |
2,552.40 | 75,659.47 | 43.69 | 14,825.80 | 12.13 | 1,251 | 59.61 | 35.26 | |
3,289.70 | 36,137.35 | 54.35 | 4,853.20 | 10.61 | 546 | -19.05 | 44.42 | |
6,387.50 | 32,718.39 | 61.69 | 2,393.10 | 12.83 | 289 | 121.77 | 51.98 | |
440.15 | 22,205.35 | 32.39 | 4,664.30 | 10.33 | 555 | 36.07 | 38.20 | |
1,478.00 | 20,158.89 | 38.96 | 8,365.80 | 7.84 | 697 | 1.73 | 34.50 | |
6,136.50 | 18,066.93 | #1 31.07 | 5,692.40 | #1 18.99 | 499 | 39.62 | 38.31 | |
409.25 | 14,839.15 | 40.22 | 7,285.40 | 14.16 | 331 | #1 189.13 | 41.52 | |
3,312.80 | 14,339.67 | 39.34 | #1 15,339.40 | 10.81 | 479 | 2.99 | 31.57 | |
1,254.40 | 14,281.13 | 62.20 | 1,448.50 | -3.77 | 160 | 11.81 | 46.71 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-3.99 %
Net Income Growth
-81.25 %
Cash Flow Change
-74.84 %
ROE
-81.31 %
ROCE
-82.30 %
EBITDA Margin (Avg.)
-49.74 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 188 | 249 | 315 | 658 | 759 | 819 | 836 |
| Fixed Assets | 0 | 67 | 111 | 120 | 160 | 196 | 427 | 526 |
| Current Assets | 0 | 114 | 133 | 184 | 436 | 312 | 298 | 265 |
| Capital Work in Progress | 0 | 6 | 5 | 10 | 52 | 231 | 77 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 |
| Other Assets | 0 | 115 | 133 | 185 | 447 | 332 | 305 | 283 |
| Total Equity & Liabilities | 0 | 188 | 249 | 315 | 658 | 759 | 819 | 836 |
| Current Liabilities | 0 | 73 | 88 | 118 | 171 | 239 | 80 | 96 |
| Non Current Liabilities | 0 | 35 | 44 | 31 | 14 | 5 | 2 | 1 |
| Total Equity | 0 | 80 | 118 | 166 | 473 | 515 | 737 | 739 |
| Reserve & Surplus | 0 | 72 | 110 | 146 | 451 | 493 | 714 | 715 |
| Share Capital | 0 | 8 | 8 | 20 | 22 | 22 | 23 | 23 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -10 | 8 | -5 | -6 | 59 | -36 | 8 | -24 |
| Investing Activities | -30 | -17 | -40 | -21 | -197 | -101 | -121 | -65 |
| Operating Activities | 13 | 7 | 25 | 20 | 20 | 28 | 98 | 25 |
| Financing Activities | 7 | 17 | 10 | -5 | 235 | 38 | 31 | 17 |
Share Holding
| % Holding | Jul 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 75.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.41 % | 4.21 % | 3.65 % | 3.37 % | 3.33 % | 3.36 % | 3.30 % | 3.26 % | 3.39 % | 4.17 % |
| DIIs | 5.52 % | 7.36 % | 7.78 % | 7.95 % | 10.56 % | 11.16 % | 11.52 % | 11.71 % | 11.07 % | 13.68 % | 13.79 % | 13.06 % | 12.84 % | 10.63 % | 6.82 % | 6.34 % | 5.46 % | 5.11 % | 3.86 % | 3.33 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 9.89 % | 6.44 % | 6.62 % | 6.35 % | 6.03 % | 5.49 % | 5.01 % | 5.09 % | 5.91 % | 6.23 % | 8.72 % | 9.38 % | 10.49 % | 12.44 % | 15.95 % | 16.33 % | 16.92 % | 17.47 % | 18.29 % | 17.91 % |
| Others | 5.42 % | 7.03 % | 6.43 % | 6.53 % | 4.24 % | 4.19 % | 4.31 % | 4.03 % | 3.85 % | 5.07 % | 1.06 % | 1.33 % | 1.00 % | 1.54 % | 1.87 % | 1.95 % | 2.30 % | 2.14 % | 2.44 % | 2.57 % |
| No of Share Holders | 11 | 89,438 | 88,311 | 89,930 | 84,358 | 76,267 | 71,958 | 70,037 | 70,799 | 71,340 | 74,628 | 74,519 | 73,730 | 73,912 | 79,623 | 79,009 | 78,393 | 76,792 | 73,331 | 68,657 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 2 | 2 | 1 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.12 | 0.19 | 0.3 | 0.09 | 0.00 |
Announcements
Copy Of Report Filed With SEBI Under Regulation 10(7) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011.Feb 25, 2026
Feb 25, 2026Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011Feb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-AcquisitionFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2026
Feb 11, 2026Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011Feb 09, 2026
Feb 09, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 09, 2026
Feb 09, 2026Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011Feb 09, 2026
Feb 09, 2026Filing Of Report Under Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 As Amended (SEBI Insider Trading Regulations)Feb 09, 2026
Feb 09, 2026Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011Jan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 24, 2026
Jan 24, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 22, 2026
Jan 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 21, 2026
Jan 21, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 21, 2026
Jan 21, 2026Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 21.01.2026Jan 21, 2026
Jan 21, 2026Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025Jan 21, 2026
Jan 21, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 12, 2026
Jan 12, 2026Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 21.01.2026Jan 12, 2026
Jan 12, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Closure of Trading WindowDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 22, 2025
Nov 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 15, 2025
Nov 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationOct 31, 2025
Oct 31, 2025Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 31, 2025
Oct 31, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 31.10.2025Oct 31, 2025
Oct 31, 2025Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025Oct 31, 2025
Oct 31, 2025Clarification On Price MovementOct 24, 2025
Oct 24, 2025Clarification Sought from Tatva Chintan Pharma Chem LtdOct 23, 2025
Oct 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2025
Oct 17, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday 31.10.2025Oct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Intimation Of Record Date Book Closure And Cut-Off Date Pursuant To Regulation 42 And 44 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Aug 26, 2025
Aug 26, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Motilal Oswal BSE 1000 Index Fund Direct-Growth | 0.00% | -18 | 0.00% | 0.00% | |
 ICICI Prudential Commodities Fund Direct - Growth | 0.00% | 0 | 0.00% | -0.18% | |
ICICI Prudential MNC Fund Direct - Growth | 0.00% | 0 | 0.00% | -0.45% | |
ICICI Prudential Smallcap Fund Direct Plan-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 Nippon India ELSS Tax Saver Fund Direct-Growth | 0.00% | 0 | 0.00% | -0.42% |
Technical Indicators
RSI(14)
Neutral 41.98
ATR(14)
Less Volatile 57.98
STOCH(9,6)
Neutral 30.16
STOCH RSI(14)
Oversold 15.89
MACD(12,26)
Bearish -5.00
ADX(14)
Weak Trend 15.53
UO(9)
Bearish 42.17
ROC(12)
Downtrend And Accelerating -6.01
WillR(14)
Neutral -71.73
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
